A previous study indicated that sorafenib treatment decreased cancer cell proliferation via inhibiting the Ras/RAF/MEK/ERK pathway [5], and in Figure 1C,D we show that the phosphorylation of ERK, P38, and MEK declined with sorafenib treatment in shlacZ control cells. Here, MAP2K7 is linked to cancer.